Asenapine: Transdermal vs Sublingual?

ASENAPINE:
TRANSDERMAL VS SUBLINGUAL

This post will summarize the key differences between the transdermal and sublingual formulation of asenapine in the following 10 minutes of video discussion.

SUMMARY:

FDA approved the transdermal asenapine formulation (SECUADO®) in 2019 and here is our website post from Oct 2019 summarizing this formulation in the following sections:

  1. Indication
  2. Dosing & Administration
  3. Application Sites
  4. Dose Conversion from Oral Asenapine
  5. Contraindications
  6. Laboratory workup.Investigations
  7. Drug Interactions
REFERENCES:
  1. Noven Pharmaceuticals, Inc. Media Press Release
  2. Carrithers, B., & El-Mallakh, R. S. (2020). Transdermal Asenapine in Schizophrenia: A Systematic Review. Patient preference and adherence, 14, 1541–1551. (pubmed)
  3. SECUADO® (asenapine) transdermal system package insert. (PDF)

INTERESTED IN LEARNING MORE?

JOIN PSYCHIATRY EDUCATION FORUM ACADEMY MEMBERSHIP

This is a closed membership for medical professionals only.

  • 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice. 
  • Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
  • Coffee Club: contain short discussions with clinical experts in the field of psychiatry.
  • Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections. 
  • Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
  • Conference Discounts: Academy members get discounted access at our conferences. 
  • Goal: is to have all important clinically relevant topics in one place for ease of access.

Related Articles